CandlesenseCandlesense
News/Companies/NEUP

NEUP News

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NEUP

(NASDAQ:NEUP) BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that Spyros Papapetropoulos, M.D., Ph.D., President and CEO, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.

August 28, 2025Investor Conference
Read more →

Neuphoria Therapeutics Q1 EPS $6.55 Up From $(2.83) YoY, Sales $15.00M

NEUP

May 20, 2025
Read more →

Neuphoria Releases Review Of 2024 And Highlights 2025 Plans Including $15M Payment From Merck Extending Company's Cash Runway To Q3 2026 And Phase 3 Affirm-1 Trial of BNC210 In Social Anxiety Disorder Progressing As Planned With Topline Readout Anticipate

NEUP

April 15, 2025
Read more →

Neuphoria Therapeutics To Ring Nasdaq Opening Bell On Monday to Mark Progress in Neuropsychiatric Treatments

NEUP

March 3, 2025
Read more →

Neuphoria Therapeutics shares are trading higher after the company announced it achieved a $15 million milestone with its Phase 2 clinical trial launch with Merck.

NEUP

February 12, 2025
Read more →

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

NEUP

February 12, 2025
Read more →

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

NEUP

February 12, 2025
Read more →

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

NEUP

December 24, 2024
Read more →